文献速递血栓与止血

癌症合并凝血因子XI缺乏患者的静脉血栓栓塞症

Venous thromboembolism in patients with cancer and factor XI deficiency.
PubMed 文献 · J Thromb Haemost · 2025-07-16

在纪念斯隆-凯特琳癌症中心开展的回顾性研究,比较73例癌症合并FXI缺乏患者与185例倾向匹配的凝血酶原时间正常的癌症对照者。12个月时VTE累积发生率分别为4.1%(95%CI 1.1%-11%)和10.6%(95%CI 6.6%-16%;Gray检验P=0.052)。FXI缺乏组手术相关大出血发生率为12.9%,对照组为2.1%。作者认为FXI缺乏似乎与癌症患者VTE风险降低相关。

要点

  • 癌症合并FXI缺乏患者12个月VTE累积发生率为4.1%(95%CI 1.1%-11%)。
  • 匹配的癌症对照者12个月VTE累积发生率为10.6%(95%CI 6.6%-16%),Gray检验P=0.052。
  • FXI缺乏组手术相关大出血发生率为12.9%,对照组为2.1%。

核心结论

  • FXI缺乏似乎与癌症患者VTE风险降低相关。

研究设计与样本

  • 在纪念斯隆-凯特琳癌症中心开展的回顾性研究。
  • 纳入癌症合并FXI缺乏患者73例,匹配的凝血酶原时间正常的癌症对照者185例。
  • 索引日期为首次至纪念斯隆-凯特琳癌症中心进行癌症评估的日期,随访至发生VTE、死亡或末次随访(以先发生者为准)。
  • 两队列按年龄、性别、索引日期前30天内手术、原发癌症部位与分期、索引时血小板和血红蛋白水平进行匹配。

主要发现

  • 12个月时FXI缺乏组VTE累积发生率为4.1%(95%CI 1.1%-11%),匹配对照组为10.6%(95%CI 6.6%-16%),Gray检验P=0.052。
  • 从索引日期至末次随访,FXI缺乏组接受手术的患者手术相关大出血发生率为12.9%,对照组为2.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Factor (F)XI deficiency is associated with reduced venous thromboembolism (VTE) risk without increased spontaneous bleeding in the general population. Factor XI inhibitors show promise in preventing VTE in orthopedic surgery and are currently being investigated in cancer-associated VTE. However, there currently are no data regarding the potential efficacy of FXI inhibition for the management of hypercoagulability in cancer. OBJECTIVES: This study aimed to evaluate the incidence of VTE among patients with cancer and FXI deficiency compared with that of a matched control population. METHODS: This is a retrospective study performed at Memorial Sloan Kettering Cancer Center evaluating VTE incidence in patients with cancer and FXI deficiency (n = 73) and matched controls with cancer and normal partial thromboplastin time (n = 185). Index date was the date of first visit at Memorial Sloan Kettering Cancer Center for cancer evaluation. Patients were followed up until VTE, death or last follow-up, whichever occurred first. Patients from the 2 cohorts were matched for age, sex, surgery within 30 days from index date, primary cancer site and stage, and platelet and hemoglobin levels at index. RESULTS: At 12 months, the cumulative incidence of VTE in the cohort with FXI deficiency was 4.1% (95% CI, 1.1%-11%) compared with 10.6% (95% CI: 6.6%-16%; Gray test, P = .052) in the matched controls. Major surgery-related bleeding occurred in 12.9% of patients with FXI deficiency undergoing surgery from the index date through the end of follow-up, compared with 2.1% in the control cohort. CONCLUSION: Factor XI deficiency appears to be associated with reduced VTE risk in individuals with cancer.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chrysafi P, Derkach A, Xirou V, et al. Venous thromboembolism in patients with cancer and factor XI deficiency. J Thromb Haemost. 2025. PMID: 40680940. doi:10.1016/j.jtha.2025.06.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。